AbbVie (NYSE:ABBV) Stock Unloaded Rep. Pete Sessions

Key Points

• Rep. Pete Sessions sold between $15,001 and $50,000 of AbbVie shares from his ET IRA account on September 14, according to a filing disclosed September 18. He also sold shares of Alphabet and Ares Capital.
• AbbVie shares opened at $265.06, near their 52-week high of $267.47. The company recently beat quarterly earnings and revenue estimates, with revenue rising 10.2% year over year.
• AbbVie declared a quarterly dividend of $1.73 per share, equivalent to a $6.92 annualized payout and a 2.6% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $276.64.

Representative Pete Sessions (Republican-Texas) recently sold shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on September 18th, the Representative disclosed that they had sold between $15,001 and $50,000 in AbbVie stock on September 14th. The trade occurred in the Representative's "ET IRA" account.

Representative Pete Sessions also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Alphabet NASDAQ: GOOGL on 9/14/2026.
• Sold $1,001 - $15,000 in shares of Ares Capital NASDAQ: ARCC on 7/24/2026.

AbbVie Stock Up 0.4%

Shares of ABBV stock opened at $265.06 on Tuesday. The firm has a 50 day moving average of $255.90 and a 200-day moving average of $232.37. The company has a market cap of $468.31 billion, a price-to-earnings ratio of 74.88, a price-to-earnings-growth ratio of 1.19 and a beta of 0.29. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business had revenue of $16.99 billion for the quarter, compared to analyst estimates of $16.80 billion. During the same period in the prior year, the firm earned $2.97 earnings per share. AbbVie's revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie's dividend payout ratio (DPR) is 195.48%.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABBV. Cantor Fitzgerald reiterated an "overweight" rating on shares of AbbVie in a report on Wednesday, September 16th. Bank of America reaffirmed a "buy" rating on shares of AbbVie in a research report on Tuesday, September 8th. JPMorgan Chase & Co. increased their price target on AbbVie from $260.00 to $280.00 and gave the company an "overweight" rating in a research report on Thursday, July 9th. UBS Group raised their price objective on AbbVie from $230.00 to $260.00 and gave the company a "neutral" rating in a research note on Monday, July 13th. Finally, BNP Paribas Exane upped their target price on shares of AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a research note on Tuesday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $276.64.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ABBV. ACT Advisors LLC. boosted its position in AbbVie by 2.5% in the second quarter. ACT Advisors LLC. now owns 1,688 shares of the company's stock valued at $425,000 after buying an additional 41 shares during the last quarter. Willner & Heller LLC increased its stake in shares of AbbVie by 0.7% in the second quarter. Willner & Heller LLC now owns 5,852 shares of the company's stock worth $1,472,000 after acquiring an additional 43 shares during the period. B.O.S.S. Retirement Advisors LLC raised its holdings in shares of AbbVie by 3.1% during the second quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company's stock worth $359,000 after purchasing an additional 43 shares during the last quarter. Fielder Capital Group LLC lifted its position in AbbVie by 1.7% during the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company's stock valued at $637,000 after purchasing an additional 43 shares during the period. Finally, Guardian Wealth Advisors LLC NC boosted its holdings in AbbVie by 0.4% in the second quarter. Guardian Wealth Advisors LLC NC now owns 11,906 shares of the company's stock valued at $2,996,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

About Representative Sessions

Pete Sessions (Republican Party) is a member of the U.S. House, representing Texas' 17th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027. Sessions (Republican Party) ran for re-election to the U.S. House to represent Texas' 17th Congressional District. He won in the general election on November 5, 2024. On October 20, 2023, Sessions announced he was running to replace Kevin McCarthy (R) as speaker of the U.S. House in the 118th Congress. Sessions lost the first round of nomination voting on October 24, 2023. Pete Sessions was born and lives in Waco, Texas. Sessions earned a B.S. from Southwestern University in 1978. Sessions' career experience includes working as an executive with AT&T.

About AbbVie

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.